新股消息 | 赜灵生物递表港交所 两种候选药物已进入3期注册性临床试验阶段

Company Overview - Zeling Bio is a late-stage clinical biotechnology company focused on integrating structural biology, artificial intelligence, and clinically relevant disease models to develop highly differentiated small molecule therapies with first-in-class or best-in-class potential [4] - The company aims to address significant unmet medical needs in the fields of hematological diseases, oncology, central nervous system, and immune/inflammatory diseases [4] - As of January 5, 2026, Zeling Bio's pipeline includes two core products (Fluorotinib and Puyisitan injection), two clinical-stage candidates (ZL-82 and ZL-85), and four preclinical candidates (ZL-65, ZL-69, ZL-59, and ZL-89) [4] Product Details - Fluorotinib (FM) is a novel triple-target inhibitor for treating myeloproliferative neoplasms, including myelofibrosis and polycythemia vera, with a focus on JAK2V617F mutations [5] - Puyisitan (PM) is a next-generation selective HDAC I/IIb inhibitor designed to meet unmet medical needs, featuring a unique non-linear triangular cap structure that enhances binding affinity and selectivity compared to approved HDAC inhibitors [5] Financial Information - Zeling Bio has not yet received approval for any products for commercial sale and has not generated any revenue from product sales [7] - For the fiscal year ending December 31, 2024, and the nine months ending September 30, 2025, the company reported other income of RMB 19.66 million and RMB 7.13 million, respectively [8] - The company incurred operating losses of RMB 91.66 million for the fiscal year ending December 31, 2024, and RMB 119.04 million for the nine months ending September 30, 2025, primarily due to R&D expenses and changes in the redemption liability [7][8] Industry Overview - The global oncology drug market is projected to grow from USD 167 billion in 2020 to USD 262.1 billion by 2024, with a compound annual growth rate (CAGR) of 11.9%, and is expected to reach USD 724.9 billion by 2035 [9] - In China, the oncology drug market is expected to grow from USD 25.8 billion in 2020 to USD 37.2 billion by 2024, with a CAGR of 13.1%, reaching USD 143.7 billion by 2035 [9] - The global myelofibrosis drug market is anticipated to grow from USD 1.6 billion in 2020 to USD 3 billion by 2024, with a CAGR of 15.9%, and is projected to reach USD 11.1 billion by 2035 [13][16]